Barbara Jóźwiak
Research Subjects
Barbara Jóźwiak has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Katarzyna Pawlak-Buś
Poznan Univ Med Sci, Dept Rheumatol Rehabil & Internal Med, Poznan, Poland
2 shared publications - Wiktor Schmidt
Department of Rheumatology, Systemic Connective Tissue Diseases and Immunotherapy of Rheumatic Diseases, J. Struś Municipal Hospital, Poznań, Poland
2 shared publications - Piotr Leszczyński
Department and Clinic of Internal Medicine and Metabolic Disorders, Poznan University of Medical Sciences, 61-701 Poznan, Poland
1 shared publication - Piotr Leszczyński
Department of Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland
1 shared publication - Zofia Czabajska
Rheumatology and Osteoporosis Ward, J. Strus Municipal Hospital, Poznań, Poland
1 shared publication
Latest Publications
- Open Access
- 22 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2429
Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience
Hyperinflammation in COVID-19 plays a crucial role in pathogenesis and severity; thus, many immunomodulatory agents are applied in its treatment. We aimed to identify good clinical response predictors of tocilizumab (TCZ) treatment in severe COVID-19, among clinical, laboratory, and radiological variables. We conducted a prospective, observational study with 120 patients with severe COVID-19 not improving despite dexamethasone (DEX) treatment. We used parametric and non-parametric statistics, univariate logistic regression, receiver operating characteristic (ROC) curves, and nonlinear factors tertile analysis. In total, 86 (71.7%) patients achieved the primary outcome of a good clinical response to TCZ. We identified forty-nine predictive factors with potential utility in patient selection and treatment monitoring. The strongest included time from symptom onset between 9 and 12 days, less than 70% of estimated radiological lung involvement, and lower activity of lactate dehydrogenase. Additional predictors were associated with respiratory function, vitamin D concentration, comorbidities, and inflammatory/organ damage biomarkers. Adverse events analysis proved the safety of such a regimen. Our study confirmed that using TCZ early in the hyperinflammatory phase, before severe respiratory failure development, is most beneficial. Considering the described predictive factors, employing simple and widely available laboratory, radiological, and clinical tools can optimize patient selection for immunomodulatory treatment with TCZ.
- 22 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2429
Open AccessIdentification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience
Hyperinflammation in COVID-19 plays a crucial role in pathogenesis and severity; thus, many immunomodulatory agents are applied in its treatment. We aimed to identify good clinical response predictors of tocilizumab (TCZ) treatment in severe COVID-19, among clinical, laboratory, and radiological variables. We conducted a prospective, observational study with 120 patients with severe COVID-19 not improving despite dexamethasone (DEX) treatment. We used parametric and non-parametric statistics, univariate logistic regression, receiver operating characteristic (ROC) curves, and nonlinear factors tertile analysis. In total, 86 (71.7%) patients achieved the primary outcome of a good clinical response to TCZ. We identified forty-nine predictive factors with potential utility in patient selection and treatment monitoring. The strongest included time from symptom onset between 9 and 12 days, less than 70% of estimated radiological lung involvement, and lower activity of lactate dehydrogenase. Additional predictors were associated with respiratory function, vitamin D concentration, comorbidities, and inflammatory/organ damage biomarkers. Adverse events analysis proved the safety of such a regimen. Our study confirmed that using TCZ early in the hyperinflammatory phase, before severe respiratory failure development, is most beneficial. Considering the described predictive factors, employing simple and widely available laboratory, radiological, and clinical tools can optimize patient selection for immunomodulatory treatment with TCZ.
- Open Access
- 5 January 2022
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 29 (2) , 274-280
On-admission laboratory predictors for developing critical COVID-19 during hospitalization – a multivariable logistic regression model
Introduction and objective: Recognition of patients with COVID-19 who will progress clinically and need respiratory support remains challenging. The aim of the study was to identify abnormalities in on-admission laboratory results that can precede progression from moderate or severe to critical...
- 5 January 2022
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 29 (2) , 274-280
Open AccessOn-admission laboratory predictors for developing critical COVID-19 during hospitalization – a multivariable logistic regression model
Introduction and objective: Recognition of patients with COVID-19 who will progress clinically and need respiratory support remains challenging. The aim of the study was to identify abnormalities in on-admission laboratory results that can precede progression from moderate or severe to critical...